Clinical Trial Data for Approved and Emerging GABA-targeting Neuroactive Steroids

With clinical recognition of the importance of neurosteroids in the modulation of GABAA signaling pathways, researchers have developed novel neuroactive steroid-based pharmacotherapies which have been tested in clinical studies and have the potential to change the treatment paradigm for MDD and PPD.
Presented by the CME Institute of Physicians Postgraduate Press, Inc. and supported by an unrestricted educational grant from Sage Therapeutics, Inc. and Biogen Inc.
Read the supplement and complete the post-test for this activity at bit.ly/3kRHmOh until March 31, 2024.
Kristina Deligiannidis, MD
Northwell Health
Glen Oaks, NY
Anita Clayton, MD
University of Virginia School of Medicine
Charlottesville, VA
____
‪@cmeinstitute‬